| Objective To analyze the efficacy of tenecteplase intravenous thrombolytic bridging intravascular thrombectomy in the treatment of acute ischemic stroke (AIS) with large vessel occlusion < 4.5 h and its influence on the outcome of the patients. Methods The clinical data of 100 AIS patients with large vessel occlusion within 4.5 hours of onset, who underwent thrombectomy at Qingdao Jiaozhou Central Hospital from June 2020 to December 2022, were retrospectively analyzed. Patients were divided into a control group (n=50, receiving direct thrombectomy) and an observation group (n=50, receiving tenecteplase intravenous thrombolysis bridging thrombectomy) based on whether intravenous thrombolysis was performed. The degree of neurological impairment, clinical efficacy, vascular revascularization rate, inflammatory factors, prognosis and complications were compared between the two groups. Results The vascular recanalization time in the observation group was shorter than that in the control group (P<0.05). NIHSS scores and levels of CRP, TNF, and IL-6 at 3 months post-treatment were lower in the observation group than in the control group (P<0.05). The clinical effective rate, 72-hour post-procedural vascular recanalization rate, and good prognosis rate were higher in the observation group than in the control group (P<0.05). The complication rate in the observation group was lower than that in the control group (P<0.05). Conclusion Tenecteplase intravenous thrombolysis bridging endovascular thrombectomy can improve the vascular recanalization rate, accelerate neurological recovery, reduce inflammatory response, decrease complications, and promote better outcomes in AIS patients with large vessel occlusion within 4.5 hours of onset. |
